Targacept, Inc. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Targacept, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Targacept, Inc. - Product Pipeline Review - 2014', provides an overview of the Targacept, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Targacept, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Targacept, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Targacept, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Targacept, Inc.'s pipeline products

Reasons to buy

- Evaluate Targacept, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Targacept, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Targacept, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Targacept, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Targacept, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Targacept, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Targacept, Inc. Snapshot 5
Targacept, Inc. Overview 5
Key Information 5
Key Facts 5
Targacept, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Targacept, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Targacept, Inc. - Pipeline Products Glance 11
Targacept, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Targacept, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Targacept, Inc. - Drug Profiles 15
dexmecamylamine 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
TC-6499 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule to Modulate Neuronal Nicotinic Acetylcholine Receptor for Addiction 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecule to Modulate Neuronal Nicotinic Acetylcholine Receptor for Parkinson Disease 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecule to Modulate Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule to Modulate Nicotinic Acetylcholine Receptor for Obesity 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
TC-7020 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
TC-8831 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Diazaspirocyclic Ligands 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Targacept, Inc. - Pipeline Analysis 26
Targacept, Inc. - Pipeline Products by Target 26
Targacept, Inc. - Pipeline Products by Route of Administration 27
Targacept, Inc. - Pipeline Products by Molecule Type 28
Targacept, Inc. - Pipeline Products by Mechanism of Action 29
Targacept, Inc. - Recent Pipeline Updates 30
Targacept, Inc. - Dormant Projects 32
Targacept, Inc. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
bradanicline 33
dexmecamylamine 33
ispronicline 33
TC-2216 34
TC-2696 34
TC-6499 34
TC-6987 34
Targacept, Inc. - Company Statement 35
Targacept, Inc. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Targacept, Inc., Key Information 5
Targacept, Inc., Key Facts 5
Targacept, Inc. - Pipeline by Indication, 2014 8
Targacept, Inc. - Pipeline by Stage of Development, 2014 9
Targacept, Inc. - Monotherapy Products in Pipeline, 2014 10
Targacept, Inc. - Phase II, 2014 11
Targacept, Inc. - Phase I, 2014 12
Targacept, Inc. - Preclinical, 2014 13
Targacept, Inc. - Discovery, 2014 14
Targacept, Inc. - Pipeline by Target, 2014 26
Targacept, Inc. - Pipeline by Route of Administration, 2014 27
Targacept, Inc. - Pipeline by Molecule Type, 2014 28
Targacept, Inc. - Pipeline Products by Mechanism of Action, 2014 29
Targacept, Inc. - Recent Pipeline Updates, 2014 30
Targacept, Inc. - Dormant Developmental Projects,2014 32
Targacept, Inc. - Discontinued Pipeline Products, 2014 33